What are the odds of losing significant vision in a lifetime?
Evidence quality 4.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 5/5
- D8 Caveat completeness
- 4/5
Lifetime probability · lifetime, global adult
1 in 6.7
15% lifetime chance
range 1 in 10 to 1 in 4.5
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Vision loss is broadly understood as an aging risk — most adults know that cataracts, macular degeneration, and glaucoma exist, and that "your eyes get worse" is a thing that happens. The specific personal odds, though, almost never get quoted. Ask a typical under-60 reader to guess their lifetime probability of ending up with significant vision impairment and the median answer clusters well under 1 in 20, when the realistic US figure is roughly 1 in 10 and the global figure for anyone who reaches old age is closer to 1 in 7. The fear is culturally present but numerically vague.
Rough estimate: Most adults estimate their personal lifetime risk at well under 1 in 20
Source: editorial intuition, not polled
Actual
~2.2 billion people globally have a near or distance vision impairment; ~43 million blind
global adults
Show derivation
Uses the WHO Blindness and Vision Impairment fact sheet headline of ~2.2 billion people globally with near or distance vision impairment as the broad prevalence anchor, and the Vision Loss Expert Group (VLEG) / GBD 2019 Lancet Global Health paper (Steinmetz et al. 2021) for the narrower category of adults 50+ with blindness or moderate-to-severe distance vision impairment: 33.6 million blind and 206 million with MSVI in 2020 among adults 50+. Two complementary routes to a lifetime figure: (a) Direct prevalence: 2.2 billion / ~6 billion adults ≈ 37% point prevalence of any vision impairment, including uncorrected refractive error and presbyopia. Restricting to "significant" impairment (moderate-to-severe distance VI or blindness) gives ~240 million / ~2 billion adults 50+ ≈ 12% point prevalence in that age band, which is the direct anchor for the ~15% global lifetime figure once cumulative incidence across remaining lifespan is added. (b) Age-stratified: US VEHSS / CDC vision-health data indicate ~12 million US adults have some vision impairment and ~1 million are blind, and the age gradient is steep — under-65 rates are low, but among adults 80+, roughly 1 in 4 to 1 in 3 has significant vision loss. Naive compounding of age-specific hazards across an adult lifespan yields ~10-12% for US adults and ~15% globally. Headline 0.15 (≈ 1 in 7) with a wide uncertainty band of 0.10 to 0.22 to span the gap between the narrow "US adult lifetime" figure (~10-12%) and the broader "global adult who lives to old age" figure (~20-25%). Scope is global_adult_lifetime because cataract- driven vision loss is overwhelmingly concentrated in LMIC populations without surgical access, which pulls the global number meaningfully above the US-only figure.
Caveats: The single biggest interpretive issue on this entry is the "preventable vs actua…
The single biggest interpretive issue on this entry is the "preventable vs actually lost" split. WHO estimates that vision loss could have been prevented or is yet to be addressed in roughly 1 billion of the 2.2 billion global cases, and the VLEG / GBD 2019 paper is clear that cataract — a condition that a single 15-minute outpatient surgery can almost entirely reverse — is the single largest cause of global blindness. The ~15% global figure therefore mixes truly lost vision (AMD, advanced glaucoma) with undertreated conditions whose cure is well-established and cheap. Treat this as two different numbers bundled into one statistic: a biological ceiling and a healthcare-access ceiling. The US figure (~10-12% lifetime) is closer to the biological ceiling because near-universal cataract surgery access removes the largest correctable cause from the denominator. The age gradient is also load-bearing: under-65 vision impairment rates are quite low, and the cumulative lifetime figure is heavily driven by what happens after 75. Anyone dying before their mid-70s from another cause never reaches peak vision-loss age, which is why the "global average" and "US adults 80+" rows in the regional breakdown differ by roughly a factor of two despite describing the same underlying hazard.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average, any significant adult-onset vision impairment | 1 in 6.7 |
MSVI-or-blindness cumulative lifetime incidence; anchored on VLEG/GBD 2019 age-50+ prevalence |
| US adult lifetime | 1 in 8.3 |
Roughly 12 million US adults with vision impairment and ~1 million blind; lifetime figure pulled down by near-universal cataract surgery access |
| LMIC — South Asia / Sub-Saharan Africa | 1 in 4.0 |
Cataract dominates; almost entirely treatable with a single outpatient surgery — the global number is partly a healthcare-access measure, not disease biology |
| US adults 80+ | 1 in 3.3 |
Vision loss is heavily concentrated in the oldest decades; roughly 1 in 3 US adults 80+ has significant impairment |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Grandparent loss in childhood
What are the odds a 9-year-old loses at least one grandparent before turning 18?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Roughly 2.2 billion people worldwide have some form of vision impairment according to the WHO, and the VLEG / GBD 2019 analysis in Lancet Global Health puts the narrower “significant” category — moderate-to-severe distance vision impairment or blindness — at about 240 million adults aged 50 and over, of whom 33.6 million are blind. Spread across a global adult lifespan and weighted for the fact that incidence climbs sharply above age 75, the lifetime probability of significant vision loss is roughly 1 in 7 globally and closer to 1 in 10 in the US, where near-universal cataract surgery removes the single largest correctable cause from the denominator. Cataract, age-related macular degeneration, glaucoma, and diabetic retinopathy dominate the causes; in the US, the CDC identifies cataract as the leading cause of vision loss and diabetic retinopathy as the leading cause of blindness in working-age adults.
The interesting thing about acquired vision loss as a global statistic is how much of it is a healthcare-access number rather than a disease-biology number. WHO estimates that vision loss could have been prevented or is yet to be addressed in roughly 1 billion of the 2.2 billion cases, and that 1 in 2 people globally who need cataract surgery do not have access to it. Cataract surgery is one of the highest-return surgical interventions in medicine — a single outpatient procedure that can almost entirely restore vision — and its unequal global distribution is what pulls the worldwide lifetime figure meaningfully above the US one. Read the ~15% global number as two numbers bundled together: an irreducible biological ceiling from AMD and advanced glaucoma, and an entirely reducible access ceiling from untreated cataract in low- and middle-income countries.
The age gradient is the other thing that matters. Under-65 significant vision impairment rates are low in every region the data covers. The cumulative lifetime figure is almost entirely driven by what happens in the last two decades of life — by the time US adults reach 80+, the cross-sectional prevalence of significant impairment approaches 1 in 3, which is why anyone who lives long enough to avoid competing mortality should not be calibrating against the global-average headline. A 55-year-old non-diabetic non-smoker with no AMD family history and regular dilated eye exams is running meaningfully below the population number; a 75-year-old with 25 years of type 2 diabetes and a smoking history is running several-fold above it. The headline is an average across a distribution that is wider than most fears in this catalogue.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] World Health Organization — Blindness and vision impairment — fact sheet
Blindness and vision impairment — fact sheet- Statistic
At least 2.2 billion people globally have a near or distance vision impairment; in at least 1 billion cases vision loss could have been prevented or is yet to be addressed; leading causes are refractive errors and cataracts; 1 in 2 people globally who need cataract surgery do not have access- Excerpt
“"Globally, at least 2.2 billion people have a near or distance vision impairment. In at least 1 billion of these, vision impairment could have been prevented or is yet to be addressed. [...] The leading causes of vision impairment and blindness are refractive errors and cataracts. [...] 1 in 2 people globally who need cataract surgery don't have access to that surgery." ”
- Source data from
- 2023-08-10
- Accessed
- 2026-04-11 · archived copy
- Calculation
- WHO's 2.2 billion / ~6 billion global adult population ≈ 37% point prevalence of *any* vision impairment, which is too broad for the "significant" framing (it includes presbyopia and uncorrected refractive error). The 1 billion preventable- or-unaddressed subset is the policy-relevant figure and the anchor for the ~90% avoidable claim in the long-form body. The single most load-bearing sentence is the "1 in 2 people globally who need cataract surgery don't have access" line, which establishes that the global number is partly a measure of healthcare access, not disease biology.
- Independence
- WHO draws on upstream VLEG / GBD data for its fact-sheet headlines; treat as partially dependent with the Steinmetz et al. 2021 source below.
-
[2] Lancet Global Health — GBD 2019 Blindness and Vision Impairment Collaborators (Steinmetz et al.) — Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study- Statistic
33.6 million cases of global blindness and 206 million cases of moderate-to-severe vision impairment (MSVI) in adults aged 50+ in 2020; leading causes globally (blindness, adults 50+) were cataract (15.2M), glaucoma (3.6M), undercorrected refractive error (2.3M), age-related macular degeneration (1.8M), and diabetic retinopathy (0.86M)- Excerpt
“"Global crude prevalence of 33·6 million cases of global blindness [in] adults aged 50 years and older in 2020. [...] 206 million aged 50 years and older adults with MSVI in 2020. [...] cataract (15·2 million cases), followed by glaucoma (3·6 million cases), undercorrected refractive error (2·3 million cases), age-related macular degeneration (1·8 million cases), diabetic retinopathy (0·86 million cases)." ”
- Source data from
- 2020-12-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Among adults aged 50+ (~2 billion globally), ~240 million have MSVI or blindness — a ~12% point prevalence in that age band. Since the 50+ hazard compounds across the remaining 30+ years of typical lifespan and shifts heavily upward above age 75, the cumulative lifetime incidence from mid-life onward is meaningfully higher than the cross-sectional point prevalence. This is the primary anchor for the 0.15 headline — it is also the source of the "cataract is the single largest cause of global blindness" claim that drives the treatability discussion in the body. Age-standardized rates of avoidable MSVI did not improve meaningfully over 2010-2019, so the WHO VISION 2020 target was missed; the absolute numbers grew because populations aged.
- Independence
- This is the VLEG / GBD 2019 paper that the WHO fact sheet above ultimately cites; the two sources share an upstream and should be treated as partially dependent. The per-cause breakdown here is the methodologically primary statement; WHO is the policy summary.
-
[3] US Centers for Disease Control and Prevention — About Common Eye Disorders and Diseases
About Common Eye Disorders and Diseases- Statistic
~20.5 million Americans 40+ have cataract in one or both eyes; ~1.8 million Americans 40+ are affected by age-related macular degeneration; ~4.1 million Americans have diabetic retinopathy and 899,000 have vision-threatening retinopathy; cataract is the leading cause of vision loss in the US and diabetic retinopathy is the leading cause of blindness in working-age Americans- Excerpt
“"An estimated 20.5 million (17.2%) Americans aged 40 years and older have cataract in one or both eyes. [...] About 1.8 million Americans aged 40 years and older are affected by AMD. [...] An estimated 4.1 million Americans have retinopathy and 899,000 have vision-threatening retinopathy. [...] Diabetic retinopathy (DR) is the leading cause of blindness in American adults of working age. [...] Cataract is [...] the leading cause of vision loss in the United States." ”
- Source data from
- 2024-05-15
- Accessed
- 2026-04-11 · archived copy
- Calculation
- US-specific disease counts that collectively sum to roughly 12 million US adults with significant impairment (including uncorrected refractive error and presbyopia-adjacent conditions) and about 1 million legally blind. Used as the US anchor in regional_breakdown and to justify the ~1-in-10 US lifetime figure as a floor. The key distinction from the global number: the majority of US cataract is surgically corrected and does not progress to blindness, which is exactly what drives the gap between the US ~10% lifetime figure and the global ~15% figure.
- Independence
- CDC Vision Health Initiative draws on the VEHSS (Vision and Eye Health Surveillance System) and NHANES, which are methodologically independent of the WHO / VLEG upstream; this is the independent US-side cross-check the schema asks for.